Adagrasib (MRTX849)

Adagrasib (MRTX849) (CAS No.: 2326521-71-3) is a synthetic small molecule and mutant selective covalent KRAS G12C inhibitor that is primarily categorized as a targeted oncology research probe for studying RAS driven signal transduction in biomedical discovery programs, with activity centered on selective modification of the cysteine residue at codon 12 in GDP bound inactive KRAS G12C to stabilize a nonproductive conformation and suppress KRAS dependent signaling networks including RAF MEK ERK and related proliferative and survival pathways in mutation defined systems; in vitro characterization across KRAS G12C driven cellular assays indicates potent pathway and growth inhibitory effects generally observed in the nanomolar to low micromolar concentration range depending on assay format, exposure time, and cellular context, and its mechanistic profile supports broad use in target validation, resistance mechanism mapping, pathway crosstalk studies, combination strategy evaluation, and compound benchmarking in engineered and endogenous KRAS G12C cell models as well as xenograft and other preclinical animal models where the concentrations or doses used in experiments typically depend on specific experimental designs and research objectives, while all use is restricted to laboratory research and drug discovery activities rather than any human consumption or other nonresearch applications.